Weight gain in women diagnosed with breast cancer

Journal of the American Dietetic Association

Volumn 97, Issue 5, 1997, Pages 519-526

  Demark Wahnefried, Wendy ^a,c   Rimer, Barbara K ^b   Winer, Eric P ^c  

^a Stedman Ctr for Nutritional Studies   (United States)

^b Detection C   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FLUOXYMESTERONE; FOLINIC ACID; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; PREDNISONE; TAMOXIFEN; VINCRISTINE;

BASAL METABOLIC RATE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DIETARY INTAKE; FEMALE; HUMAN; PHYSICAL ACTIVITY; PREVALENCE; QUALITY OF LIFE; REVIEW; THERMOGENESIS; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0030989125     PISSN: 00028223     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-8223(97)00133-8     Document Type: Review

References (83)

1. Wingo PAC, Tong T, Bolden S. Cancer statistics 1995. Cancer J Clin. 1995;45:8-30.
2. American Cancer Society. Cancer Facts and Figures. Atlanta, Ga: American Cancer Society; 1997.
3. Knobf MK, Mullen JC, Xistris D, Moritz PA. Weight gain in women with breast cancer receiving adjuvant chemotherapy. Oncol Nurs Forum. 1983;10:28-34.
4. Huntington MO. Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast. Cancer. 1985;56:472-474.
5. Pronzato P, Brema F, Amorosa D, Bertelli G, Conte PF, Martini MC, Pastorino G, Rooso R. Megestrol acetate: phase II study of a single daily administration in advanced breast cancer. Breast Cancer Res Treat. 1990;17:51-54.
6. Camoriano JK, Loprinzi CL, Ingle JN, Therneau T, Krook J, Veeder M. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990;8:1327-1334.
7. Chlebowski RT, Rose D, Buzzard IM, Blackburn G, Insull W, Grosvenor M, Elashoff R, Wynder E. Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. Breast Cancer Res Treat. 1991;20:73-84.
8. Chlebowski RT, Weiner JM, Reynolds R, Luce J, Bulcavage L, Bateman L. Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat. 1986;7:23-29.
9. Cruz JM, Muss HB, Brockschmidt JK, Evans G. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. Semin Oncol. 1990; 17:63-67.
10. DeConti RC. Weight gain in the adjuvant chemotherapy of breast cancer. Proc Am Soc Clin Oncol. 1982;1:73. Abstract.
11. Dixon J, Moritz D, Baker F. Breast cancer and weight gain: an unexpected finding. Oncol Nurs Forum. 1978;5:5-7.
12. Donegan WL, Hartz AJ, Rimm AA. The association of body weight and recurrent cancer of the breast. Cancer. 1978;41:1590-1594.
13. Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1993;11:1418-1429.
14. Goodwin PA, Panzarella T, Boyd NF. Weight gain in women with localized breast cancer - a descriptive study. Breast Cancer Res Treat. 1988;11:59-66.
15. Bonadonna G, Valagussa P, Rossi A. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat. 1985;5:95-115.
16. Foltz AT. Weight gain among stage II breast cancer patients: a study of five factors. Oncol Nurs Forum. 1985;12:21-26.
17. Grindel CG, Cahill CA, Walker M. Food intake of women with breast cancer during their first six months of chemotherapy. Oncol Nurs Forum. 1989;16:401-407.
18. Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, Boyd N. Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 1985;5:195-200.
19. Hernandez BM, Bonomi P, Hoeltgen T, Bennett JM. Weight gain during adjuvant therapy for stage II breast cancer. Proc Am Soc Clin Oncol. 1983;2:108. Abstract.
20. Levine EG, Raczynski JM, Carpenter JT. Weight gain with breast cancer adjuvant treatment. Cancer. 1991;67:1954-1959.
21. Knobf MT. Symptoms and rehabilitation needs of patients with early stage breast cancer during primary therapy. Cancer. 1990;66:1392-1401.
22. Morgan LR. Megestrol acetate versus tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol. 1985;12:43-47.
23. Fisher B, Costantino J, Redmond C. A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479-484.
24. Hoskin PJ, Ashley S, Yarnold JR. Weight gain after primary surgery for breast cancer - effect of tamoxifen. Breast Cancer Res Treat. 1992;22:129-132.
25. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Maillard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE. Combination hormonal therapy with tamoxifen plus fluoxymestrone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. Cancer. 1991;67:886-891.
26. Aisner J, Parner H, Tait N, Hickman M, Forrest A, Greco FA, Tchekmedyian NS. Appetite stimulation and weight gain with megestrol acetate. Semin Oncol. 1990;17:2-7.
27. Davila E, Vogel CL, East D, Cairns V, Hilsenbeck S. Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988;61:2161-2167.
28. Gundersen S, Kvinnsland S, Klepp O. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced breast cancer. Dev Oncol. 1987;51:187-191.
29. Iino Y, Takeo T, Sugamata N, Aoyagi H, Takai Y, Takei H, Ando T, Koibuchi Y, Yokoe T, Ohwada S. Oral high-dose medroxyprogesterone acetate treatment for recurrent breast cancer. Anticancer Res. 1995;15:1061-1064.
30. Kornblith AB, Hollis DR, Zuckerman E, Lyss AP, Canellos GP, Cooper MR, Herndon JE, Phillips CA, Abrams J, Aisner J. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol. 1993;11:2081-2089.
31. Muss HB, Case LD, Capizzi RL. High-versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1990;8:1797-1805.
32. Dryenforth S, Wooley O, Wooley S. A woman's body in a man's world: a review of findings on body image and weight control. In: Kaplan JR, ed. A Woman's Conflict: The Special Relationship Between Women and Food. Englewood Cliffs, NJ: Prentice-Hall; 1989:205-239.
33. Ganz PA, Schag CC, Polinsky ML. Rehabilitation needs and breast cancer: the first month after primary therapy. Breast Cancer Res Treat. 1987;10:243-253.
34. Monnin S, Schiller MR, Sachs L, Smith AM. Nutritional concerns of women with breast cancer. J Cancer Educ. 1993;8:63-89.
35. Demark-Wahnefried W, Hars V, Conaway M, Havlin K, Rimer B, McElveen G, Winer EP. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr. 1997;65:1495-1501.
36. Tannenbaum A. Relationship of body weight to cancer incidence. Arch Path. 1940;30:509-515.
37. Goodwin PJ, Boyd NF. Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat. 1990;16:205-214.
38. Newcomb PA, Klein R, Klein BE, Haffner S, Mares-Perlman J, Cruickshanks KJ, Marcus PM. Association of dietary and lifestyle factors with sex hormones in postmenopausal women. Epidemiology. 1995;6:209-211.
39. Ballard-Barbash R, Schatzkin A, Taylor LR, Kahle LL. Association of change in body mass with breast cancer. Cancer Res. 1990;50:2152-2155.
40. Abe R, Kumagi N, Kimura M, Hirosaki A, Nakamura T. Biological characteristics of breast cancer in obesity. Tokyo J Exp Med. 1976;120:351-359.
41. Bastarrachea J, Kau S, Hortobagyi GN. Obesity - a poor prognostic factor in primary breast cancer. Proc Am Soc Clin Oncol. 1988;7:37. Abstract.
42. Eberlein T, Simon R, Fisher S, Lippman ME. Height, weight, and risk of breast cancer relapse. Breast Cancer Res Treat. 1985;5:81-86.
43. Enriori CL, Orsini W, del Carmen MC. Decrease of circulating level of SHBG in postmenopausal obese women as a risk factor in breast cancer: reversible effect of weight loss. Gynecol Oncol. 1986;23:77-86.
44. McNee RK, Mason BH, Neave LM. Influence of height, weight, and obesity on breast cancer incidence and recurrence in Auckland, New Zealand. Breast Cancer Res Treat. 1987;9:145-150.
45. Senie RT, Rosen PP, Rhodes P. Obesity at diagnosis of breast carcinoma influences duration of disease-free survival. Ann Intern Med. 1992;116:26-32.
46. Stanford JL, Szklo M, Brinton LA. Estrogen receptors and breast cancer. Epidemiology. 1986;8:42-59.
47. Tarttner PI, Papatestas AE, Ioannovich J, Mulvihill M, Lesnick G, Aufses A. Cholesterol and obesity as prognostic factors in breast cancer. Cancer. 1981;47:2222-2227.
48. Verreault R, Brisson J, Deschenes L, Naud F. Body weight and prognostic indicators in breast cancer. Am J Epidemiol. 1989;129:260-268.
49. de Waard F, Poortman J, Collette BJ. Relationship of weight to the promotion of breast cancer after menopause. Nutr Cancer. 1981;2:237-240.
50. Tretli S, Haldorsen T, Ottestad L. The effect of pre-morbid height and weight on the survival of breast cancer patients. Br J Cancer. 1990;62:299-304.
51. Morabia A, Wynder E. Epidemiology and natural history of breast cancer. Surg Clin North Am. 1990;70:739-751.
52. Bruning P, Bonfrer J, Hart A. Nonprotein-bound estradiol, sex hormone binding globulin, breast cancer and breast cancer risk. Br J Cancer. 1985;51:479-484.
53. Ingram DM, Nottage E, Ng S, Sparrow L, Roberts A, Willcox D. Obesity and breast disease: the role of the female sex hormones. Cancer. 1989;64:1049-1053.
54. Ota D, Jones L, Jackson G, Jackson P, Kemp K, Bauman D. Obesity, nonprotein-bound estradiol levels and distribution of estradiol in the sera of breast cancer patients. Cancer. 1986;57:558-562.
55. Schapira D, Kumar N, Lyman G. Obesity, body fat distribution and sex hormones in breast cancer patients. Cancer. 1991;67:2215-2218.
56. Pugeat M, Crave JC, Elmidani M, Nicholas MH, Garoscio-Cholet M, Lejeune H, Dechaud H, Tourniaire J. Pathophysiology of sex hormone binding globulin (SHBG): relationship to insulin. J Steroid Biochem Mol Biol. 1991;40:841-849.
57. Kirschner MA, Schnieder G, Ertel NH, Worton E. Obesity, androgens, estrogens and cancer risk. Cancer Res. 1982;42:3281-3285.
58. Wang DY, Rubens RD, Clark GMG. Effects of prednisolone on sex hormone binding globulin during primary endocrine treatment of advanced breast cancer. Breast Cancer Res Treat. 1988;11:67-70.
59. Maki PA, Newberne PM. Dietary lipids and immune function. J Nutr. 1992;122:610-614.
60. Kuller LH. Eating fat or being fat and risk of cardiovascular disease and cancer among women. Ann Epidemiol. 1994;4:119-127.
61. Brewin T. Can a tumor cause the same appetite perversion or taste change as pregnancy? Lancet. 1980;2:907-908.
62. Mukhopadhyay MG, Larkin S. Weight gain in cancer patients on chemotherapy. Proc Am Soc Clin Oncol. 1986;5:254. Abstract.
63. Shah M, Jeffery RW. Is obesity due to overeating and inactivity, or to a defective metabolic rate? A review. Ann Behav Med. 1991;13:73-81.
64. Meyerowitz B, Sparks F, Spears I. Adjuvant chemotherapy for breast carcinoma. Cancer. 1979;43:1613-1617.
65. Silberfarb P. Psychological aspects of neoplastic disease. Am J Psychiatry. 1980;137:450-455.
66. Albanes D, Conway J, Taylor P, Moe P, Judd J. Validation and comparison of eight physical activity questionnaires. Epidemiology. 1990;1:65-71.
67. Arbeit JM, Lees DE, Corsey R, Brennan MF. Resting energy expenditure in controls and cancer patients with localized and diffuse disease. Ann Surg. 1984;199:292-298.
68. Knox LS, Crosby LO, Feurer IP, Buzby GP, Miller CL, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg. 1983;197:152-162.
69. Buzzard IM, Asp EH, Chlebowski RT, Boyar AP, Jeffrey RW, Nixon DW, Blackburn GL, Jochimsen PR, Scanlon EF, Insull W, Elashoff RM, Butrum R, Wynder EL. Diet intervention methods to reduce fat intake: nutrient and food group composition of self-selected low-fat diets. J Am Diet Assoc. 1990;90:42-53.
70. Chlebowski RT, Blackburn GL, Buzzard IM, Insull W, Grosvenor M, Elashoff RM, Wynder EL. Evaluation of dietary fat reduction as secondary breast cancer prevention. In: Engstrom P, ed. Advances in Cancer Control, VII: Screening and Prevention Research. New York, NY: Wiley-Liss; 1990:201-209.
71. Chlebowski RT, Blackburn GL, Nixon DW, Jochimson P, Scanlon EF, Insull W, Buzzard IM, Wynder EL, Elashoff RM. Unpublished data summaries and the design and conduct of clinical trials. Control Clin Trials. 1989;10:368-377.
72. Gorbach SL, Morrill-LaBrode A, Woods MN, Dwyer JT, Selles WD, Henderson M, Insull W, Goldman S, Thompson D, Clifford C. Changes in food patterns during a low-fat dietary intervention in women. J Am Diet Assoc. 1990;90:802-809.
73. Insull W, Henderson MM, Prentice RL, Buzzard IM, Chlebowski RT, Blackburn GL, Elashoff RM, Wynder EL. Results of a randomized feasibility study of a low-fat diet. Arch Intern Med. 1990;150:421-427.
74. Nordevang E, Callmer E, Marmur A, Holm LE. Dietary intervention in breast cancer patients: effects of food choice. Eur J Clin Nutr. 1992; 46:387-396.
75. Nordevang E, Ikkala E, Callmer E, Marmur A. Dietary intervention in breast cancer patients: effects on dietary habits and nutrient intake. Eur J Clin Nutr. 1990;44:861-867.
76. Prentice R, Thompson D, Clifford C, Gorbach S, Goldin B, Byar D. Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. J Natl Cancer Inst. 1990;82:129-134.
77. Sheppard L, Kristal AR, Kushi LH. Weight loss in women participating in randomized trial of low-fat diets. Am J Clin Nutr. 1991;54:821-828.
78. Wynder EL, Morabia A, Rose DP, Cohen LA. Clinical trials of dietary interventions to enhance cancer survival. In: Mettlin CJ, Aoki E, eds. Recent Progress in Research cm Nutrition and Cancer. New York, NY: Wiley-Liss; 1990:217-229.
79. Wynder EL, Taioli E, Rose DP. Breast cancer - the optimal diet. In: Jacobs MM, ed. Exercise, Fat and Cancer. New York, NY: Plenum; 1992:143-153.
80. Ingle JN, Everson LK, Wieand HS. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node positive breast cancer. J Clin Oncol. 1988;6:1388-1396.
81. Subramian VP, Raich PC, Walker BK. Weight gain in breast cancer patients undergoing chemotherapy. Breast Cancer Res Treat. 1981;1:170. Abstract.
82. Tormey DC, Taylor SG, Kalish LA. Adjuvant systemic therapy in premenopausal and postmenopausal women with node-positive breast cancer. In: Salmon SE, ed. Adjuvant Therapy of Cancer. 3rd ed. Philadelphia, Pa: Grune & Stratton; 1984:359-368.
83. Ingle JN, Krook JE, Schaid DJ. Randomized trial in postmenopausal women with node positive breast cancer: Observation versus adjuvant therapy with cyclophosphamide (C), 5-fluorouracil (F), prednisone (P), with or without tamoxifen (T). Results with seven year median follow-up. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. In: Salmon SE, ed. Adjuvant Therapy of Cancer. 4th ed. Orlando, Fla: Grune & Stratton; 1990:216-225.